Latest Abcuro News & Updates

See the latest news and media coverage for Abcuro. We track all announcements, press releases, and industry mentions in real time, all in one place.

Abcuro

Clinical-stage biotechnology company developing precision antibody therapies

abcuro.com

Company type: Private company
Number of employees: 51–200
Industry: Pharmaceuticals

Last updated August 18

Latest news about Abcuro

In short: Abcuro reported MUSCLE results missing the primary endpoint and raised $66 million for a registrational trial.

Company announcements

August 18 Abcuro

Abcuro raises $66 million for IBM treatment study

Funds support a potentially registrational trial of ulviprubart in less severe inclusion body myositis patients starting late 2026.

April 19 Abcuro

Abcuro presents Phase 2/3 ulviprubart study topline results

The study covers design, patient characteristics, and results for inclusion body myositis. Published April 19, 2026.

April 3 Abcuro

Abcuro presents phase 2/3 ulviprubart study results

Study misses primary IBMFRS endpoint but shows trends of slowed progression in less severe patients. Ulviprubart depletes target T cells with favorable safety.

March 26 Abcuro

Abcuro presents topline results of ulviprubart Phase 2/3 study

The study focuses on inclusion body myositis, covering design, patient characteristics, and results.

Media coverage

August 14 Endpoints News

Abcuro gets $66M for Phase 3 in muscle-weakening condition

Abcuro has collected $66 million a few months after saying its sole drug missed the mark in inclusion body myositis, but had found hope in...

March 4 Rheumatology Advisor

Ulviprubart Fails to Meet Endpoints in Inclusion Body Myositis Study

Topline results from the MUSCLE study indicate that ulviprubart did not meet its primary endpoint of mean change in inclusion body myositis functional rating scale...

February 24 FierceBiotech

Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study

A year after Abcuro raised $200 million to fund a phase 2/3 muscle disease trial of its anti-KLRG1 antibody, the study has...

February 10, 2025 Endpoints News

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro went to its board to explore a...

Never miss news about Abcuro

Track Abcuro and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Abcuro competitors & trending companies

Browse news for competitors to Abcuro and other trending companies.